Aktiia Secures USD 30M in Funding

Aktiia, a Neuchâtel, Switzerland-based HealthTech company providing optical blood pressure monitoring devices, raised USD 30M in funding.

The round was led by Redalpine, with participation from Khosla Ventures, Molten, Translink Capital, Verve, and 415 Capital.

The company intends to use the funds to accelerate its mission to ease the global burden of hypertension by providing insights into blood pressure management through AI-driven technology, currently used by over 60,000 customers and healthcare organizations.

Founded by Drs. Mattia Bertschi (CEO) and Josep Solà (CTO), Aktiia provides a CE-marked device that is currently available in seven European markets and approved as a medical device in 44 countries worldwide. Its technology offers innovation and ease in blood pressure data collection and machine learning modeling, giving personalized, continuous, and medical-grade blood pressure and heart rate data.  The company empowers people, researchers, and clinicians with blood pressure data paving the way for novel understanding and personalized patient care of hypertension.

In conjunction with this funding, Aktiia added Daniel Graf as its new President and Board Member.